Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP708506.RAwu9ReTaDIJg_QgtGcp0ftSU9IWW9MdJsj4U36MMwRHU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP708506.RAwu9ReTaDIJg_QgtGcp0ftSU9IWW9MdJsj4U36MMwRHU130_assertion type Assertion NP708506.RAwu9ReTaDIJg_QgtGcp0ftSU9IWW9MdJsj4U36MMwRHU130_head.
- NP708506.RAwu9ReTaDIJg_QgtGcp0ftSU9IWW9MdJsj4U36MMwRHU130_assertion description "[Further, unlike the benefits observed with CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphomas (PTCL), other than ALK-positive ALCL, are relatively chemoresistant to this regimen.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP708506.RAwu9ReTaDIJg_QgtGcp0ftSU9IWW9MdJsj4U36MMwRHU130_provenance.
- NP708506.RAwu9ReTaDIJg_QgtGcp0ftSU9IWW9MdJsj4U36MMwRHU130_assertion evidence source_evidence_literature NP708506.RAwu9ReTaDIJg_QgtGcp0ftSU9IWW9MdJsj4U36MMwRHU130_provenance.
- NP708506.RAwu9ReTaDIJg_QgtGcp0ftSU9IWW9MdJsj4U36MMwRHU130_assertion SIO_000772 19074097 NP708506.RAwu9ReTaDIJg_QgtGcp0ftSU9IWW9MdJsj4U36MMwRHU130_provenance.
- NP708506.RAwu9ReTaDIJg_QgtGcp0ftSU9IWW9MdJsj4U36MMwRHU130_assertion wasDerivedFrom befree-2016 NP708506.RAwu9ReTaDIJg_QgtGcp0ftSU9IWW9MdJsj4U36MMwRHU130_provenance.
- NP708506.RAwu9ReTaDIJg_QgtGcp0ftSU9IWW9MdJsj4U36MMwRHU130_assertion wasGeneratedBy ECO_0000203 NP708506.RAwu9ReTaDIJg_QgtGcp0ftSU9IWW9MdJsj4U36MMwRHU130_provenance.